The FDA rejected Zealand Pharma’s short bowel syndrome drug, and asked the company to run another trial before it reconsiders. The FDA told Zealand it
Pfizer is targeting a steady 2025, promising pipeline trims, cost cuts and smaller deals as it works to reassure investors about its path forward. …
A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal hyperplasia, a condition marked
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Advisors to the FDA had difficulty dissecting a small but concerning set of safety data from Moderna’s pediatric RSV vaccine data, largely concluding that other
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Arjun Goyal and Stefan Vitorovic, two of Vida Ventures’ three co-founding managing directors, have exited the firm as it rejigs its leadership team seven years
In his first major interview since securing another term in the White House, President-elect Donald Trump reiterated concerns with the disproven link between childhood vaccines
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS